Xencor (XNCR) Corporate presentation summary

Financial position and partnerships

• Maintains a strong financial position with approximately $486.4 million in cash and equivalents as of June 30, 2026, supporting ongoing R&D and clinical programs.

• Multiple commercialized and late-stage partnered programs generate milestone and royalty revenues, offsetting internal development costs.

• Key partnerships with AstraZeneca, Amgen, Zenas, Astellas, Vir, and Johnson & Johnson provide significant milestone and royalty potential.

Clinical pipeline and innovation

• XmAb® engineering platforms enable rapid, modular drug design for oncology and autoimmune diseases, with a focus on T-cell engagers and novel antibodies.

• Lead oncology candidates include XmAb819 (ENPP3 x CD3) for ccRCC and XmAb541 (CLDN6 x CD3) with XmAb808 (B7-H3 x CD28) for ovarian cancer.

• Immunology pipeline features XmAb942 (TL1A) and XmAb412 (TL1A x IL23p19) targeting IBD and other autoimmune indications.

Key clinical data and milestones

• XmAb819 achieved a 25% ORR in heavily pretreated ccRCC patients, supporting progression to pivotal studies in 2027.

• XmAb541 monotherapy showed 14% ORR in ovarian cancer and 28% in germ cell tumors; combination with XmAb808 is advancing.

• XmAb942 demonstrated best-in-class safety, pharmacokinetics, and immunogenicity in Phase 1, supporting a 12-week dosing interval in IBD.

• XmAb412, a bispecific TL1A x IL23p19 antibody, is positioned for best-in-class potential in IBD, with first-in-human studies starting in 2026.